早期肝素给药在ARDS治疗中的作用探索:基于MIMIC-IV数据库分析
该回顾性队列研究利用MIMIC-IV数据库,纳入ICU入住72小时内接受预防性肝素的ARDS患者,采用倾向性评分匹配和逆概率加权(IPW)分析评估早期肝素使用对死亡率的影响。接受预防性肝素者住院死亡率显著低于未使用者(13.55% vs 17.93%,HR=0.71,95%CI 0.54-0.93,P=0.012),倾向性评分匹配后结果仍显著(12.75% vs 17.93%,HR=0.65,95%CI 0.47-0.90,P=0.010)。五种统计模型均显示早期肝素显著降低住院死亡率。作者认为早期预防性肝素可能大幅降低ARDS患者死亡率,为临床治疗提供新思路。
要点
- ARDS患者入ICU 72小时内接受预防性肝素者住院死亡率13.55%,未使用者17.93%(HR=0.71,95%CI 0.54-0.93,P=0.012)。
- 倾向性评分匹配后住院死亡率12.75% vs 17.93%(HR=0.65,95%CI 0.47-0.90,P=0.010)。
- 五种统计模型均显示早期肝素降低住院死亡率:双稳健模型(未平衡协变量)HR=0.669(95%CI 0.487-0.919,P=0.013);全协变量模型HR=0.705(95%CI 0.515-0.965,P=0.029);IPW模型HR=0.660(95%CI 0.491-0.888,P=0.006);倾向性评分匹配模型HR=0.650(95%CI 0.470-0.900,P=0.010);
- 次要结局显示肝素使用还与60天和90天死亡率降低相关。
- 作者认为早期预防性肝素可能大幅降低ARDS患者死亡率,凸显其作为ARDS管理关键组分的潜力。
适用人群与场景
- MIMIC-IV数据库中ICU入住72小时内接受预防性肝素的ARDS患者。
研究设计与关键结果
- 研究类型:回顾性队列研究,使用MIMIC-IV数据库。
- 干预与对照:ARDS患者入ICU 72小时内接受预防性肝素 vs 未接受。
- 主要终点:住院死亡率,肝素组13.55% vs 未使用组17.93%(HR=0.71,95%CI 0.54-0.93,P=0.012)。
- 倾向性评分匹配后住院死亡率:肝素组12.75% vs 未使用组17.93%(HR=0.65,95%CI 0.47-0.90,P=0.010)。
- 五种统计模型均显示早期肝素显著降低住院死亡率:双稳健模型(未平衡协变量)HR=0.669(95%CI 0.487-0.919,P=0.013);全协变量模型HR=0.705(95%CI 0.515-0.965,P=0.029);IPW模型HR=0.660(95%CI 0.491-0.888,P=0.006);倾向性评分匹配模型HR=0.650(95%CI 0.470-0.900,P=0.010);多因素Cox回归模型HR=0.706(95%CI 0.536-0.930,P=0.013)。
- 次要结局:肝素使用还与60天和90天死亡率降低相关。
证据类型、等级与局限
- 证据类型:回顾性队列研究(MIMIC-IV数据库分析)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为早期预防性肝素可能大幅降低ARDS患者死亡率,凸显其作为ARDS管理关键组分的潜力,为临床治疗提供新视角和新策略。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Acute respiratory distress syndrome (ARDS) is a severe respiratory condition characterized by a high mortality rate, the management of which relies on supportive care and a profound understanding of its pathophysiology. Heparin, with its anticoagulant and potential anti-inflammatory properties, offers a new therapeutic opportunity for the treatment of ARDS.
METHODS: In this retrospective cohort study, we examined the MIMIC-IV database for ARDS patients who received prophylactic heparin within the first 72 h of ICU admission. Employing propensity score matching and inverse probability weighting (IPW) analysis, we evaluated the impact of early heparin use on patient outcomes, focusing on mortality rates.
RESULTS: Patients who received prophylactic heparin had a significantly lower in-hospital mortality rate compared to those who did not (13.55% vs 17.93%, HR = 0.71, 95% CI: 0.54-0.93, P = 0.012). This result remained significant after propensity score matching (12.75% vs 17.93%, HR = 0.65, 95% CI 0.47-0.90, P = 0.010). Analysis using five different statistical models indicated that early use of heparin significantly reduced the in-hospital mortality rate, with HR = 0.669 (95% CI 0.487-0.919, P = 0.013) in the doubly robust model without balanced covariates; HR = 0.705 (95% CI 0.515-0.965, P = 0.029) with all covariates considered; HR = 0.660 (95% CI 0.491-0.888, P = 0.006) in the propensity score (IPW) model; HR = 0.650 (95% CI 0.470-0.900, P = 0.010) in the propensity score matching model; and HR = 0.706 (95% CI 0.536-0.930, P = 0.013) in the multivariate Cox regression model. Secondary outcomes indicated that heparin use was also associated with reduced mortality rates at 60 days, and 90 days.
CONCLUSION: This research highlights that early prophylactic administration of heparin may substantially lower mortality in ARDS patients. These findings underscore the potential of heparin as a key component in the management of ARDS, offering a new perspective and novel strategies for clinical treatment.
参考来源
- Xiao LX, Zhu L, Chen J, et al. Exploring the therapeutic role of early heparin administration in ARDS management: a MIMIC-IV database analysis. J Intensive Care. 2024. PMID: 38409068. doi:10.1186/s40560-024-00723-5
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。